Mitsubishi Chemical Holdings Corporation (MCHC) was jointly established by Mitsubishi Chemical Corporation and Mitsubishi Pharma Corporation by means of a stock-for-stock exchange effective in October 2005. Then, Mitsubishi Tanabe Pharma Corporation formed by the merger between Mitsubishi Pharma Corporation and Tanabe Seiyaku Co., Ltd. has started operations on October 1, 2007. Further, functional products businesses of the MCHC Group has been restructured and consolidated as a new company, Mitsubishi Plastics, Inc. on April 1, 2008.
Along with these, the MCHC Group now consists of three core business companies: Mitsubishi Chemical Corporation, Mitsubishi Plastics, Inc., and Mitsubishi Tanabe Pharma Corporation, including their Group companies. As the holding company, MCHC will further develop and enhance its Group portfolio management to increase the Group value.
As of October 1, 2007
| Company name | Mitsubishi Chemical Holdings Corporation Organization |
|---|---|
| Head office | 14-1 Shiba 4-chome, Minato-ku, Tokyo 108-0014 MAP |
| Establishment | October 3, 2005 |
| Paid-in capital | 50 billion yen |
| Listings | Tokyo Stock Exchange, Osaka Securities Exchange |
| Fiscal year end | March 31 |
| Main scope of business | Management of Group companies |
As of October 1, 2007
| Company name | Mitsubishi Chemical Corporation |
|---|---|
| Head office | 14-1 Shiba 4-chome, Minato-ku, Tokyo 108-0014 |
| Incorporation | October 1, 1994 (Establishment: June 1, 1950) |
| Paid-in capital | 50 billion yen |
| Line of Business (consolidated) | Petrochemicals, Performance and functional products, Health care, and Others |
| Shareholder | Mitsubishi Chemical Holdings Corporation 100% |
As of February 18, 2008
| Company name | Mitsubishi Plastics, Inc. |
|---|---|
| Head office | 2-2 Nihonbashi Hongokucho 1-chome, Chuo-ku, Tokyo 103-0021 |
| Establishment | January 15, 1943 (Inauguration: February 1, 1946) |
| Paid-in capital | 21.5 billion yen |
| Line of Business | Synthetic plastic products |
| Shareholder | Mitsubishi Chemical Holdings Corporation 100% |
As of October 1, 2009
| Company name | Mitsubishi Tanabe Pharma Corporation |
|---|---|
| Head office | 6-18 Kitahama 2-chome, Chuo-ku, Osaka 541-8505 |
| Incorporation | October 1, 2007 |
| Paid-in capital | 50 billion yen |
| Listings | Tokyo Stock Exchange, Osaka Securities Exchange |
| Fiscal year end | March 31 |
| Line of Business | Ethical pharmaceuticals and other pharmaceuticals |
| Shareholder | Mitsubishi Chemical Holdings Corporation 56.36% |
The MCHC Group has three business domains: Performance Products, Health Care and Chemicals, and operates businesses with three core business companies.
| Business domains | Segments | Outlines | Major products | Business companies |
|---|---|---|---|---|
Performance Products |
Electronics Applications | In businesses of the Electronics Applications Segment, we deliver a variety of high-value-added products in the fields of information and electronics. Known for the Verbatim brand in recording media, we are pursuing a leadership position in the Blu-ray Disc markets. | ·Optical recording media |
Mitsubishi Chemical Corporation Mitsubishi Plastics, Inc. |
| Designed Materials | The businesses of the Designed Materials Segment boast considerable accumulated knowledge in polymer processing and composite technology, as well as carbon chemistry, and handles a broad range of processed resin and film products. In addition, we provide environment and energy and food ingredients businesses. In recent years, polyester films, plastic-metal composite plates, polyvinyl chloride plates and carbon fiber products have been contribution to business performance, particularly for liquid crystal display businesses. | ·Li-ion battery materials |
Mitsubishi Chemical Corporation Mitsubishi Plastics, Inc. |
|
| Health Care | Health Care | Mitsubishi Tanabe Pharma Corporation forms the core of businesses in the Health Care Segment, that our R&D capabilities are significantly strong. Leveraging our competitive advantage to have diagnostics and safety assessment areas, Mitsubishi Chemical Medience Corporation, we are cultivating our expertise in the emerging field of personalized medicine by integrating the pharmaceuticals and diagnostic functions. | ·Anti-TNF α monoclonal antibody Remicade |
Mitsubishi Chemical Corporation Mitsubishi Tanabe Pharma Corporation |
Chemicals |
Chemicals | In businesses of the Chemicals Segment, we provide a variety of basic chemicals and carbon materials. | ·Purified terephthalic acid (PTA) |
Mitsubishi Chemical Corporation |
| Polymers | Utilizing our unique strengths in marketing, product development and production technology, our derivative products respond to advanced and specific client needs. | ·Polypropylene |
